How do Eliquis and Pradaxa work?
Eliquis (apixaban) and Pradaxa (dabigatran) are both direct oral anticoagulants (DOACs) that prevent blood clots by inhibiting specific clotting factors. Eliquis targets factor Xa, a key protein in the clotting cascade. Pradaxa directly blocks thrombin (factor IIa), the enzyme that converts fibrinogen to fibrin for clot formation. This difference affects their reversal agents: Eliquis uses Andexxa (andexanet alfa), while Pradaxa has Praxbind (idarucizumab).[1][2]
What are they approved to treat?
Both drugs treat nonvalvular atrial fibrillation to reduce stroke and systemic embolism risk, and prevent deep vein thrombosis (DVT) after hip or knee replacement surgery. Eliquis also treats DVT and pulmonary embolism (PE), and reduces recurrence risk. Pradaxa has broader venous thromboembolism (VTE) prevention approvals, including acute treatment in some cases.[1][2][3]
How do dosing and administration differ?
Eliquis comes as 2.5 mg or 5 mg tablets, typically twice daily with food optional. Pradaxa is a 75 mg, 110 mg, or 150 mg capsule, twice daily, but must be taken without food crushed or opened due to stomach acid sensitivity—patients with swallowing issues need alternatives. Dose adjustments vary by age, kidney function, and weight; both require monitoring renal function.[1][2]
| Feature | Eliquis (apixaban) | Pradaxa (dabigatran) |
|---------|---------------------|-----------------------|
| Standard AFib dose | 5 mg twice daily | 150 mg twice daily |
| Food requirement | No | Empty stomach |
| Renal adjustment | Yes (CrCl 15-29 mL/min: reduce) | Yes (CrCl 15-30: 75 mg BID) |
| Form | Tablet | Capsule only |
What about bleeding risk and reversibility?
Both carry major bleeding risks (around 2-3% per year in trials), but Pradaxa showed higher GI bleeding rates in some studies like RE-LY (1.6% vs. 1.1% for warfarin), while Eliquis had lower overall bleeding in ARISTOTLE (2.13% vs. 3.09% warfarin). Eliquis reversal is faster with Andexxa; Pradaxa's Praxbind fully reverses it within minutes. No routine blood monitoring needed for either, unlike warfarin.[1][3][4]
Cost and availability differences
Eliquis costs about $500-600 for 30 days without insurance; Pradaxa is similar at $500+. Generics aren't available yet—Eliquis patents expire around 2026-2028, Pradaxa in 2024-2026 in major markets (check DrugPatentWatch.com for updates).[5] Patient assistance programs exist from Bristol-Myers Squibb/Pfizer (Eliquis) and Boehringer Ingelheim (Pradaxa).
When might doctors choose one over the other?
Eliquis suits patients with GI bleed history or poor adherence (easier dosing). Pradaxa fits those needing quick reversal or with factor Xa inhibitor intolerance. Kidney function guides choice: avoid Pradaxa if CrCl <30 mL/min long-term. Real-world data shows Eliquis with slightly better persistence due to tolerability.[3][4]
Sources:
[1] Eliquis.com prescribing info
[2] Pradaxa.com prescribing info
[3] NEJM ARISTOTLE/RE-LY trials
[4] AHA DOAC comparisons
[5] DrugPatentWatch.com